The Medical Letter on Drugs and Therapeutics
- In Brief: Auvi-Q Epinephrine Auto-Injector for Infants and Toddlers
- Clenpiq - A Low-Volume Sodium Picosulfate-Based Colonoscopy Preparation
- Trelegy Ellipta - A Three-Drug Inhaler for COPD
- Clarithromycin in Patients with Coronary Artery Disease
- In Brief: Restrictions on Essure
- Inotuzumab Ozogamicin (Besponsa) - An Antibody-Drug Conjugate for ALL (online only)
In Brief: Auvi-Q Epinephrine Auto-Injector for Infants and Toddlers
May 21, 2018 (Issue: 1547)The FDA has approved a lower-dose epinephrine auto-injector (Auvi-Q 0.1 mg – Kaléo) for emergency treatment of anaphylaxis in children weighing 7.5-15 kg (16.5-33 lbs). It is the first epinephrine auto-injector to be approved for use in infants...more
- Drugs for allergic disorders. Med Lett Drugs Ther 2017; 59:71.
- SH Sicherer and FER Simons et al. Epinephrine for first-aid management of anaphylaxis. Pediatrics 2017; 139:e20164006.
- S Lee et al. Update on biphasic anaphylaxis. Curr Opin Allergy Clin Immunol 2016; 16:346.
- H Kim et al. Inadequacy of current pediatric epinephrine autoinjector needle length for use in infants and toddlers. Ann Allergy Asthma Immunol 2017; 118:719.
- S Dreborg et al. Epinephrine auto-injector needle lengths: can both subcutaneous and periosteal/intraosseous injection be avoided? Ann Allergy Asthma Immunol 2018 Feb 27 (epub).
- FE Simons et al. Epinephrine absorption in children with a history of anaphylaxis. J Allergy Clin Immunol 1998; 101:33.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.